Search - tctmd.com

Displaying 441 - 460 of 1569

Sort: Relevancy | Date

Presentation TCT 2019

Long-Term Antithrombotic Therapy After PCI: How Do I Incorporate COMPASS Into My Practice?

Presenter: Robert Welsh

September 26, 2019

Presentation TCT 2019

De-Escalation: When and How? — The Role of Platelet Function and Genetic Testing

Presenter: Francesco Franchi

September 26, 2019

Presentation TCT 2019

TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor-Plus-Aspirin Beginning at 3 Months in High-Risk Patients Undergoing PCI

Presenter: Roxana Mehran

September 26, 2019

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

Presentation TCT 2019

Insights From SMART CHOICE

Presenter: Joo-Yong Hahn

September 26, 2019

Presentation TCT 2019

Insights From STOP DAPT-2

Presenter: Takeshi Kimura

September 26, 2019

Presentation TCT 2019

Insights From TWILIGHT

Presenter: Usman Baber

September 26, 2019

Presentation TCT 2019

Insights From GLOBAL LEADERS and GLASSY

Presenter: Pascal Vranckx

September 26, 2019

Presentation TCT 2019

Short and Ultrashort DAPT Strategies After Stent Implantation: What Do We Know and Where Are We Going?

Presenter: Robert Byrne

September 26, 2019

Presentation TCT 2019

Case Introduction: DAPT Dilemma After a Complex PCI in a High Bleeding Risk Patient

Presenter: Amit Vora

September 26, 2019

News Industry News

CeleCor Therapeutics Announces Positive First-in-Human Data of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor, Presented at TCT 2019

September 25, 2019

News Daily News

Bleeding on Low-Dose Antithrombotic Therapy a ‘Red Flag’ for New Cancers

Yael L. Maxwell

September 20, 2019

News Daily News

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

Caitlin E. Cox

September 20, 2019

News Conference News TCT 2019

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

Shelley Wood

September 19, 2019

News Opinion Fellow Talk

What I Am Most Looking Forward to at TCT 2019

Mahesh V. Madhavan, MD

September 18, 2019

News Conference News ESC 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

Todd Neale

September 11, 2019

News Conference News ESC 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

Todd Neale

September 10, 2019

News Conference News ESC 2019

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Yael L. Maxwell

September 10, 2019

News Conference News ESC 2019

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

Caitlin E. Cox

September 06, 2019

News Conference News ESC 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Michael O'Riordan

September 05, 2019

Advertisement

Long-Term Antithrombotic Therapy After PCI: How Do I Incorporate COMPASS Into My Practice?

De-Escalation: When and How? — The Role of Platelet Function and Genetic Testing

TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor-Plus-Aspirin Beginning at 3 Months in High-Risk Patients Undergoing PCI

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Insights From SMART CHOICE

Insights From STOP DAPT-2

Insights From TWILIGHT

Insights From GLOBAL LEADERS and GLASSY

Short and Ultrashort DAPT Strategies After Stent Implantation: What Do We Know and Where Are We Going?

Case Introduction: DAPT Dilemma After a Complex PCI in a High Bleeding Risk Patient

CeleCor Therapeutics Announces Positive First-in-Human Data of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor, Presented at TCT 2019

Bleeding on Low-Dose Antithrombotic Therapy a ‘Red Flag’ for New Cancers

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

What I Am Most Looking Forward to at TCT 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content